Results for the intent-to-treat population; includes 619 patients (25.2%) who crossed over to letrozole from tamoxifen. § Results for the censored population (with 95% CI); excludes crossover ...

Aromatase inhibitors are a group of endocrine agents that lower the ... monthly in women with hormone receptor positive breast cancer that has recurred. Tamoxifen belongs to a group of drugs known as ...

Around 80% of breast cancers are ER+ and are treated with anti-oestrogen therapies such as tamoxifen and aromatase inhibitors. But around one in five of these cases recur within 10 years, and nearly ...

Aromatase inhibitors (AIs) are becoming the hormonal ... or anastrozole versus the previous standard of 5 years of adjuvant tamoxifen and support using an AI (exemestane, anastrozole or letrozole ...